Karyopharm Therapeutics (KPTI) Tops Q2 EPS by 1c; Offers FY22 Revenue Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St futures muted as oil gains curb risk appetite after S&P record close
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- Reddit to join S&P 500 index on Aug. 18, shares leap
Karyopharm Reports Second Quarter 2022 Financial Results and Highlights Recent Company Progress
August 4, 2022 7:30 AM EDTAchieved Second Quarter 2022 Total Revenue of $39.7 Million, Up 76% Versus Second Quarter 2021;
XPOVIO® (selinexor) Net Product Revenue of $29.0 Million, a 44% Increase Over Q2 2021
 Received Full Marketing Authorization from the European Commission Expanding Indication for NEXPOVIO® (selinexor) for Treatment of Adults with Multiple Myeloma Who Have Received at Least One Prior Therapy
Clinical Updates from Phase 1/2 Study of Selinexor in Combination with Ruxolitinib in Treatment-Naïve Myelofibrosis and Interim Data from Phase 2 Study Evaluating Eltanexor in Relapsed/Refractory MDS Expected in 2H 2022
Company Provides... More
